Taiwan Biomaterial Co., Ltd. AI Stock Analysis
Taiwan Biomaterial Co., Ltd. (6649) AI Stock Analysis
Taiwan Biomaterial Co., Ltd.
(TPEx:6649)
The overall score of 64 reflects a company with exceptional recent financial performance and a rock-solid balance sheet, offset by significant technical weakness and a high valuation that leaves little room for error. The dramatic profitability turnaround and strong cash flows are the most significant positive factors, but the stock's bearish momentum and premium P/E ratio introduce substantial caution. The sustainability of the recent growth surge remains the key question for investors.
Taiwan Biomaterial Co., Ltd. (6649) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.49B
- Dividend Yield
- 2.82%
- Average Volume (3M)
- 39.84K
- Price to Earnings (P/E)
- 190.5
- Beta (1Y)
- 0.26
- Revenue Growth
- -24.55%
- EPS Growth
- -85.90%
- Country
- TW
- Employees
- 46
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
Taiwan Biomaterial Co., Ltd. Business Overview & Revenue Model
Company Description
Taiwan Biomaterial Co., Ltd., established in 2010 and based in Zhubei, Taiwan, focuses on the innovation, development, and commercialization of medical devices throughout Taiwan. Their product offerings include Foamagen, a pioneering dural substitute...
Taiwan Biomaterial Co., Ltd. Financial Statement Overview
Summary
The company has undergone a dramatic financial transformation, swinging to strong profitability with revenue surging over 128% and net margins turning positive at 26.7%. The balance sheet is a fortress with minimal debt (D/E 0.08), and operating cash flow has turned robustly positive. The primary risk is the sustainability of this explosive, single-year turnaround given a history of volatility.
Income Statement
78PositiveBalance Sheet
85Very PositiveCash Flow
75Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 153.37M | 220.40M | 96.57M | 72.84M | 127.31M | 41.67M |
| Gross Profit | 69.06M | 123.10M | 57.31M | 47.12M | 76.09M | 21.09M |
| EBITDA | 8.46M | 76.30M | 15.99M | 9.71M | 51.63M | -35.35M |
| Net Income | 8.02M | 58.93M | -1.73M | -10.13M | 33.76M | -47.44M |
Balance Sheet | ||||||
| Total Assets | 732.07M | 789.95M | 704.56M | 716.28M | 735.31M | 553.79M |
| Cash, Cash Equivalents and Short-Term Investments | 205.97M | 355.90M | 312.84M | 304.18M | 332.65M | 152.65M |
| Total Debt | 50.91M | 52.59M | 56.99M | 60.70M | 68.51M | 79.64M |
| Total Liabilities | 84.72M | 104.86M | 78.39M | 88.38M | 88.89M | 130.89M |
| Stockholders Equity | 647.35M | 685.09M | 626.16M | 627.89M | 646.42M | 422.89M |
Cash Flow | ||||||
| Free Cash Flow | -110.44M | 47.33M | 13.78M | -13.38M | -2.45M | -61.71M |
| Operating Cash Flow | -69.11M | 48.77M | 18.43M | -10.16M | 35.02M | -32.01M |
| Investing Cash Flow | 48.90M | 6.95M | 20.53M | 13.98M | -120.55M | 48.34M |
| Financing Cash Flow | -44.82M | -2.66M | -5.29M | -15.29M | 177.03M | 4.51M |
Taiwan Biomaterial Co., Ltd. Peers Comparison
Overall Rating
TW:316471Outperform
TW:473567Neutral
TW:664964Neutral
TW:643138Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 71Outperform | TWD 1.43B | 23.05 | ― | 4.82% | 1.32% | 80.16% | |
| 67Neutral | TWD 1.38B | 5.91 | ― | 10.54% | 17.43% | 131.46% | |
| 64Neutral | TWD 1.49B | 190.49 | ― | 2.82% | -24.55% | -85.90% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 38Underperform | TWD 1.63B | -9.78 | ― | ― | 11.20% | 21.91% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6649 | Taiwan Biomaterial Co., Ltd. | 35.45 | -15.06 | -29.81% | |
| TW:3164 | GenMont Biotech, Inc. | 16.60 | -1.30 | -7.26% | |
| TW:4735 | Avita Corporation | 35.10 | 5.59 | 18.93% | |
| TW:6431 | Kuangli Bio-Tech Holdings Co., Ltd. | 16.75 | 0.55 | 3.40% | |
| TW:6864 | Anti-Microbial Savior BioteQ Co., Ltd. | 37.00 | -43.00 | -53.75% | |
| TW:7806 | Gin Hwa Biotech, Inc. | 48.00 | -11.22 | -18.94% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026
